Ovulation inhibition by estetrol in an in vivo model - PubMed
Comparative Study
Ovulation inhibition by estetrol in an in vivo model
Herjan J T Coelingh Bennink et al. Contraception. 2008 Mar.
Abstract
Background: Currently, the synthetic steroid ethinylestradiol (EE) is the preferred estrogen in combined oral contraceptives. The aim of the present study was to evaluate the effectiveness of the natural steroid estetrol (E(4)) as an ovulation inhibitor in rats when compared to EE.
Study design: Regularly cycling female rats were treated orally twice daily for four consecutive days, starting on the day of estrus, with E(4) (0.03, 0.1, 0.3, 1.0 or 3.0 mg/kg), EE (0.0003, 0.001, 0.003, 0.01 or 0.03 mg/kg) or vehicle control (eight animals per group). In a second experiment conducted under the same experimental protocol, 2.0 mg/kg of E(4) was administered as a single daily dose or as a dose of 1.0 mg/kg twice daily. In both studies, the primary end point was the number of ovulated oocytes in the genital tract.
Results: Estetrol at the twice daily dose of 0.3 mg/kg and above inhibited ovulation. This effect was statistically significant (p<.05). The comparator, EE, significantly inhibited ovulation (p<.05) at the highest dose (0.03 mg/kg) administered twice daily. An E4 dose of 2.0 mg/kg administered once daily for four consecutive days inhibited ovulation in four of eight rats. In contrast, when the same dose was administered in two separate doses, that is, 1.0 mg/kg twice daily, ovulation was inhibited in eight of eight rats. The ED(50) for the EE and the E(4) dose response curves shows that EE is 18 times more potent than E(4).
Conclusion: Twice daily administration of E(4) effectively inhibits ovulation in cycling rats. The effect is dose-dependent. The relative potency of E(4) is about 18 times less compared to that of EE. We conclude that based on these data, combined with available pharmacological and clinical data on the safety and efficacy of E(4), the human fetal estrogenic steroid estetrol is a potential candidate to replace EE in combined oral contraceptives.
Similar articles
-
Ovulation inhibition by estetrol in an in vivo model.
Coelingh Bennink HJT, Skouby S, Bouchard P, Holinka CF. Coelingh Bennink HJT, et al. Climacteric. 2008;11(sup1):30. doi: 10.1080/13697130802040366. Climacteric. 2008. PMID: 28485646
-
Oral bioavailability and bone-sparing effects of estetrol in an osteoporosis model.
Coelingh Bennink HJ, Heegaard AM, Visser M, Holinka CF, Christiansen C. Coelingh Bennink HJ, et al. Climacteric. 2008;11 Suppl 1:2-14. doi: 10.1080/13697130701798692. Climacteric. 2008. PMID: 18464016
-
Estrogenic uterovaginal effects of oral estetrol in the modified Allen-Doisy test.
Heegaard AM, Holinka CF, Kenemans P, Coelingh Bennink HJ. Heegaard AM, et al. Climacteric. 2008;11 Suppl 1:22-8. doi: 10.1080/13697130701842490. Climacteric. 2008. PMID: 18464018
-
Complete and robust ovulation inhibition with NuvaRing.
Killick S. Killick S. Eur J Contracept Reprod Health Care. 2002 Dec;7 Suppl 2:13-8; discussion 37-9. Eur J Contracept Reprod Health Care. 2002. PMID: 12659397 Review.
-
Comparison of estrogenic components used for hormonal contraception.
Stanczyk FZ, Winer SA, Foidart JM, Archer DF. Stanczyk FZ, et al. Contraception. 2024 Feb;130:110310. doi: 10.1016/j.contraception.2023.110310. Epub 2023 Oct 18. Contraception. 2024. PMID: 37863464 Review.
Cited by
-
Estetrol: A New Choice for Contraception.
Fruzzetti F, Fidecicchi T, Montt Guevara MM, Simoncini T. Fruzzetti F, et al. J Clin Med. 2021 Nov 29;10(23):5625. doi: 10.3390/jcm10235625. J Clin Med. 2021. PMID: 34884326 Free PMC article. Review.
-
Gérard C, Foidart JM. Gérard C, et al. Drugs R D. 2023 Jun;23(2):77-92. doi: 10.1007/s40268-023-00419-5. Epub 2023 May 3. Drugs R D. 2023. PMID: 37133685 Free PMC article. Review.
-
Abot A, Fontaine C, Buscato M, Solinhac R, Flouriot G, Fabre A, Drougard A, Rajan S, Laine M, Milon A, Muller I, Henrion D, Adlanmerini M, Valéra MC, Gompel A, Gerard C, Péqueux C, Mestdagt M, Raymond-Letron I, Knauf C, Ferriere F, Valet P, Gourdy P, Katzenellenbogen BS, Katzenellenbogen JA, Lenfant F, Greene GL, Foidart JM, Arnal JF. Abot A, et al. EMBO Mol Med. 2014 Oct;6(10):1328-46. doi: 10.15252/emmm.201404112. EMBO Mol Med. 2014. PMID: 25214462 Free PMC article.
-
Zou Y, Lu Q, Zheng D, Chu Z, Liu Z, Chen H, Ruan Q, Ge X, Zhang Z, Wang X, Lou W, Huang Y, Wang Y, Huang X, Liu Z, Xie W, Zhou Y, Yao P. Zou Y, et al. Mol Autism. 2017 Aug 17;8:46. doi: 10.1186/s13229-017-0159-3. eCollection 2017. Mol Autism. 2017. PMID: 28824796 Free PMC article.
-
Schmidt M, Lenhard H, Hoenig A, Zimmerman Y, Krijgh J, Jansen M, Coelingh Bennink HJT. Schmidt M, et al. J Cancer Res Clin Oncol. 2021 Jun;147(6):1833-1842. doi: 10.1007/s00432-020-03472-8. Epub 2020 Nov 26. J Cancer Res Clin Oncol. 2021. PMID: 33242131 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources